HLB바이오스텝

278650KOSDAQ자연과학 및 공학 연구개발업

58.0 / 100

Reference Date: 2026-07-24

Financial Score21.0 / 40

News Sentiment20.0 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: PBR is significantly undervalued vs. peers but Operating Profit is on a declining trend. Plunged 35.0% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

HLB Biosstep specializes in non-clinical CRO services, particularly in efficacy evaluation for pharmaceutical development, leveraging its expertise in high-complexity experiments using major animals like pigs and beagles. The company expanded its offerings in 2024 by acquiring HLB BioCode, a GLP toxicity testing specialist, and also provides animal facility construction and maintenance services.

Number of Employees

150people

Average Salary

61.7M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

0.31Industry Average 2.527.0Point

Half of industry avg (excellent)

ROE

-18.60Industry Average -32.093.5Point

Below industry avg

Debt Ratio

6.60Industry Average 7.314.0Point

In line with industry avg

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲18.7% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼441.2% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -9.2% (declining, 3yr)

Detailed News Sentiment

2 totalPositive 2Neutral 0Negative 0Average Sentiment Score 80

Positive
HLB바이오스텝, 통합 비임상 서비스로 파킨슨병 신약 IND 승인 지원
HLB바이오스텝의 파킨슨병 치료제 후보물질이 임상 1상 IND 승인을 받아 긍정적인 시장 반응을 기대할 수 있다.
Positive
HLB그룹 경영진 계열사 지분 매수 행보…HLB바이오스텝 백성진 대표 ...
HLB바이오스텝의 대표이사가 추가 주식 매수를 통해 기업에 대한 신뢰와 긍정적인 시장 반응을 시사합니다.

Detailed Momentum

52-week position1.0Point

Near 52w low (19%, downtrend)

Current 1,809Won52-week high 4,78552-week low 1,099

1-month return0.0Point

1m -35.04% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-07-22
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-21
Neutral주요사항보고서(자기전환사채만기전취득결정)2026-07-21
Neutral주요사항보고서(자기전환사채만기전취득결정)2026-07-14
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-07-01